チョメイナ カンガイ ハツイク オ シメシタ カンケッカンシュ ノ 1レイ

Giant hemangiomas of the liver with the diameter of more then 10 cm are likely to grow rapidly with bleeding in tumor and concur a terrible complication such as heavy bleeding caused by tumor rupture. We experienced a case of giant hemangioma of the liver with a pronounced extrahepatic growth. A 33-year-old woman consulted a doctor because of common cold and was pointed out having hepatomegaly. She was admitted to the hospital for further examination. Abdominal ultrasonography showed a heterogenous high echoic tumor with even surface lying ventral to the gallbladder from the margin inferior hepatis. Abdominal CT scan showed a low density tumor which growed from S4, 5 and 6 of the liver to extrahepatic area. The tumor was confirmed to show low intensity on T1-weighted images and remarkable high intensity on T2-weighted images on a magneticresonance imaging scan and had strong contract effect from the edge by a contract medium. It showed cotton wool like appearance on an angiography. It was diagnosed as hemangioma of the liver and a partial hepatic resection was conducted. The resected tumor was rubiginous, spongy, 11×5.5×7.5 cm in size and 660g in weight. Histopathologically, it was diagnosed as cavernous hemangioma

Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol

Introduction Conventional cancer registries are suitable for simple surveillance of cancer patients, including disease frequency and distribution, demographics, and prognosis; however, the collected data are inadequate to clarify comprehensively diverse clinical questions in daily practice. Methods We constructed an umbrella‐type lung cancer patient registry (CS‐Lung‐003) integrating multiple related prospective observational studies (linked studies) that reflect clinical questions about lung cancer treatment. The primary endpoint of this registry is to clarify daily clinical practice patterns in lung cancer treatment; a key inclusion criterion is pathologically diagnosed lung cancer. Under this registry, indispensable clinical items are detected in advance across all active linked studies and gathered prospectively and systematically to avoid excessive or insufficient data collection. Researchers are to input information mutually, irrespective of the relevance to each researcher's own study. Linked studies under the umbrella of the CS‐Lung‐003 registry will be updated annually with newly raised clinical questions; some linked studies will be newly created, while others will be deleted after the completion of the analysis. Enrollment began in July 2017. Discussion We successfully launched the umbrella‐type CS‐Lung‐003 registry. Under this single registry, researchers collaborate on patient registration and data provision for their own and other studies. Thus, the registry will produce results for multiple domains of study, providing answers to questions about lung cancer treatment raised by other researchers. Through such analysis of each linked study, this registry will contribute to the comprehensive elucidation of actual daily practice patterns in lung cancer treatment. Key points CS‐Lung‐003 registry directly integrates multiple linked studies created under the umbrella of this cancer registry to solve various clinical questions regarding daily practice patterns of lung cancer treatment

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

Purpose Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not treated with ICIs, and of those who benefit from immunotherapy in EGFR-mutant NSCLC. Methods We analyzed patients with unresectable stage III/IV or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type lung cancer registry (CS-Lung-003). Results A total of 303 patients who met the eligibility criteria were analyzed. The median age was 69 years; 116 patients were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group than in the ICI group (17.1 vs. 12.7 months, p  Conclusion ICIs were administered to only 22% of patients with EGFR-mutated lung cancer, and they had shorter TTNT of EGFR-TKI compared to other patients. ICI treatment should be avoided in EGFR mutated lung cancer with poor PS but can be considered for lung cancer with EGFR minor mutations. Pathological biomarker to predict long-term responders to ICI are needed.<br

High-Pressure Diffusion Control: Na Extraction from NaAlB₁₄

A novel synthesis technique, called the high-pressure diffusion control (HPDC) method, was developed in this study. The method combined the high-pressure synthesis using a cubic anvil apparatus and an anisotropic diffusion control technique; the electrical processing in high-pressure and high-temperature environments of up to 4 GPa and over 1000 °C is enabled by simultaneously adjusting the temperature, pressure, and voltage. This nonequilibrium state is effective in creating metastable materials. The developed novel technique was applied to polycrystalline NaAlB14 with a boron covalent framework. Although electronic conduction is dominant in this material and no Na-ion conduction is observed even at high temperatures, the HPDC method successfully extracted Na ions by utilizing the difference in bond strength between Na and B, creating the metastable material AlB14 while maintaining its basic crystal structure. During the decrease in the Na concentration, applying a high pressure compressed the sample according to the volume change and maintained good contact at the intergrain boundary in the polycrystalline sample, promoting Na-ion diffusion. The Na extraction functioned as electron carrier modulation and significantly reduced the electrical resistivity. The developed HPDC method is expected to be applicable to various compounds with a difference in the bond strength between constituent elements and has the potential to open up new avenues in the inorganic synthesis of polycrystalline metastable materials with dense sintered states and modulate their physical properties

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

Purpose Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not treated with ICIs, and of those who benefit from immunotherapy in EGFR-mutant NSCLC. Methods We analyzed patients with unresectable stage III/IV or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type lung cancer registry (CS-Lung-003). Results A total of 303 patients who met the eligibility criteria were analyzed. The median age was 69 years; 116 patients were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group than in the ICI group (17.1 vs. 12.7 months, p  Conclusion ICIs were administered to only 22% of patients with EGFR-mutated lung cancer, and they had shorter TTNT of EGFR-TKI compared to other patients. ICI treatment should be avoided in EGFR mutated lung cancer with poor PS but can be considered for lung cancer with EGFR minor mutations. Pathological biomarker to predict long-term responders to ICI are needed.<br